Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
accepted:
09
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
aheadofprint
Résumé
Axicabtagene ciloleucel (axi-cel, Yescarta) is an autologous, anti-CD19, chimeric antigen receptor (CAR) T-cell therapy approved for patients with relapsed and refractory non-Hodgkin's lymphoma. Substantial inter-individual variability in cellular kinetics has been observed with CAR-T therapies and factors impacting CAR-T cellular kinetics remain poorly understood. This work reports a population cellular kinetic model of axi-cel in relapsed and patients with refractory non-Hodgkin's lymphoma and investigated the impact of covariates on early and late kinetic phases of CAR-T exposure. A population cellular kinetic model (NONMEM Axi-cel cellular kinetics were well described by a piecewise model of cellular growth kinetics characterized by an exponential growth phase followed by a triphasic decline phase including a long-term persistence phase. The final cellular kinetic model retained in vitro doubling time during CAR-T cell manufacturing and total number of T cells infused as covariates impacting the duration of the growth phase, which, however, did not substantially influence maximum concentration, area under the concentration-time curve over the first 28 days, or long-term persistence. A statistically significant relationship was observed between maximum concentration and the probability to receive tocilizumab and/or corticosteroids. No covariates considered in this study were found to significantly and substantially predict the exposure profile of axi-cel. Tocilizumab and steroid use were related to maximum concentration, but they were used reactively to treat toxicities that are associated with a higher maximum concentration. Further CAR-T kinetic analyses should consider additional factors to explain the observed variability in cellular kinetics or help establish a dose-exposure relationship. NCT02348216 (ZUMA-1), NCT03105336 (ZUMA-5), and NCT03391466 (ZUMA-7).
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Axicabtagene ciloleucel (axi-cel, Yescarta) is an autologous, anti-CD19, chimeric antigen receptor (CAR) T-cell therapy approved for patients with relapsed and refractory non-Hodgkin's lymphoma. Substantial inter-individual variability in cellular kinetics has been observed with CAR-T therapies and factors impacting CAR-T cellular kinetics remain poorly understood. This work reports a population cellular kinetic model of axi-cel in relapsed and patients with refractory non-Hodgkin's lymphoma and investigated the impact of covariates on early and late kinetic phases of CAR-T exposure.
METHODS
METHODS
A population cellular kinetic model (NONMEM
RESULTS
RESULTS
Axi-cel cellular kinetics were well described by a piecewise model of cellular growth kinetics characterized by an exponential growth phase followed by a triphasic decline phase including a long-term persistence phase. The final cellular kinetic model retained in vitro doubling time during CAR-T cell manufacturing and total number of T cells infused as covariates impacting the duration of the growth phase, which, however, did not substantially influence maximum concentration, area under the concentration-time curve over the first 28 days, or long-term persistence. A statistically significant relationship was observed between maximum concentration and the probability to receive tocilizumab and/or corticosteroids.
CONCLUSIONS
CONCLUSIONS
No covariates considered in this study were found to significantly and substantially predict the exposure profile of axi-cel. Tocilizumab and steroid use were related to maximum concentration, but they were used reactively to treat toxicities that are associated with a higher maximum concentration. Further CAR-T kinetic analyses should consider additional factors to explain the observed variability in cellular kinetics or help establish a dose-exposure relationship.
CLINICAL TRIAL REGISTRATION
BACKGROUND
NCT02348216 (ZUMA-1), NCT03105336 (ZUMA-5), and NCT03391466 (ZUMA-7).
Identifiants
pubmed: 39240498
doi: 10.1007/s40262-024-01413-z
pii: 10.1007/s40262-024-01413-z
doi:
Banques de données
ClinicalTrials.gov
['NCT02348216', 'NCT03105336', 'NCT03391466']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
US FDA. US prescribing information: Yescarta (axicabtagene ciloleucel). Santa Monica (CA): Kite Pharma, Inc; 2022. Available from: https://www.fda.gov/media/108377/download . Accessed 31 Jan 2023.
King AC, Orozco JS. Axicabtagene ciloleucel: the first FDA-approved CAR T-cell therapy for relapsed/refractory large B-cell lymphoma. J Adv Pract Oncol. 2019;10:878–82.
pubmed: 33425471
pmcid: 7517758
Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96:1295–312.
doi: 10.1002/ajh.26301
pubmed: 34310745
pmcid: 9290945
Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36.
doi: 10.1186/2162-3619-1-36
pubmed: 23210908
pmcid: 3520838
Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–98.
doi: 10.1158/2159-8290.CD-12-0548
pubmed: 23550147
pmcid: 3667586
Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 Anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther J Am Soc Gene Ther. 2017;25:285–95.
doi: 10.1016/j.ymthe.2016.10.020
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.
doi: 10.1056/NEJMoa1707447
pubmed: 29226797
pmcid: 5882485
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91–103.
doi: 10.1016/S1470-2045(21)00591-X
pubmed: 34895487
Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54.
doi: 10.1056/NEJMoa2116133
pubmed: 34891224
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20:31–42.
doi: 10.1016/S1470-2045(18)30864-7
pubmed: 30518502
Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. 5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). Blood. 2023; p. blood.2022018893.
Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales M-A, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389:148–57.
doi: 10.1056/NEJMoa2301665
pubmed: 37272527
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95.
doi: 10.1182/blood-2014-05-552729
pubmed: 24876563
pmcid: 4093680
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.
doi: 10.1038/s41408-021-00459-7
pubmed: 33824268
Tallantyre EC, Evans NA, Parry-Jones J, Morgan MPG, Jones CH, Ingram W. Neurological updates: neurological complications of CAR-T therapy. J Neurol. 2021;268:1544–54.
doi: 10.1007/s00415-020-10237-3
pubmed: 33140239
US Food and Drug Administration. Center for Biologics Evaluation and Research. Considerations for the development of chimeric antigen receptor (CAR) T cell products. Draft guidance for industry. 2022. Available from: https://www.fda.gov/media/156896/download . Accessed 2 Jul 2023.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products. EMEA/149995/2008 rev.1.; 2018. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products-revision_en.pdf . Accessed 2 Jul 2023.
Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:4898–911.
doi: 10.1182/bloodadvances.2020002394
pubmed: 33035333
pmcid: 7556133
Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504.
doi: 10.1023/A:1012299115260
pubmed: 11768292
Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558–69.
doi: 10.1208/s12248-009-9133-0
pubmed: 19649712
pmcid: 2758126
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.
doi: 10.1200/JCO.2006.09.2403
pubmed: 17242396
Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137:3272–6.
doi: 10.1182/blood.2020008865
pubmed: 33534891
pmcid: 8351896
Nguyen THT, Mouksassi M-S, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacomet Syst Pharmacol. 2017;6:87–109.
doi: 10.1002/psp4.12161
Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–51.
doi: 10.1208/s12248-011-9255-z
pubmed: 21302010
pmcid: 3085712
Ogasawara K, Dodds M, Mack T, Lymp J, Dell’Aringa J, Smith J. Population cellular kinetics of lisocabtagene maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with Rrlapsed/refractory large B-cell lymphoma. Clin Pharmacokinet. 2021;60:1621–33.
doi: 10.1007/s40262-021-01039-5
pubmed: 34125421
pmcid: 8613160
De Boer RJ, Perelson AS. Quantifying T lymphocyte turnover. J Theor Biol. 2013;327:45–87.
doi: 10.1016/j.jtbi.2012.12.025
pubmed: 23313150
pmcid: 3640348
Singh AP, Zheng X, Lin-Schmidt X, Chen W, Carpenter TJ, Zong A, et al. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. MAbs. 2020;12:1688616.
doi: 10.1080/19420862.2019.1688616
pubmed: 31852337
Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16.
doi: 10.1056/NEJMoa2024850
pubmed: 33626253
Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, et al. Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells. CPT Pharmacomet Syst Pharmacol. 2019;8:285–95.
doi: 10.1002/psp4.12388
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331–42.
doi: 10.1056/NEJMoa1914347
pubmed: 32242358
pmcid: 7731441
Liu C, Ayyar VS, Zheng X, Chen W, Zheng S, Mody H, et al. Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans. Clin Pharmacol Ther. 2021;109:716–27.
doi: 10.1002/cpt.2040
pubmed: 33002189
Mu W, Long X, Cai H, Chen C, Hu G, Lou Y, et al. A model perspective explanation of the long-term sustainability of a fully human BCMA-targeting CAR (CT103A) T-cell immunotherapy. Front Pharmacol. 2022;13: 803693.
doi: 10.3389/fphar.2022.803693
pubmed: 35185564
pmcid: 8847740
Zhang Y, Li J, Lou X, Chen X, Yu Z, Kang L, et al. A prospective investigation of bispecific CD19/22 CAR T cell therapy in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Front Oncol. 2021;11: 664421.
doi: 10.3389/fonc.2021.664421
pubmed: 34113569
pmcid: 8185372
Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020;4:560–72.
doi: 10.1182/bloodadvances.2019000525
pubmed: 32045475
pmcid: 7013261
Wu LS, Su Y, Li C, Zhou W, Jackson CC, Sun Y-N, et al. Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma. Clin Transl Sci. 2022;15:3000–11.
doi: 10.1111/cts.13421
pubmed: 36204820
pmcid: 9747118
Ahmed JH, Makonnen E, Bisaso RK, Mukonzo JK, Fotoohi A, Aseffa A, et al. Population pharmacokinetic, pharmacogenetic, and pharmacodynamic analysis of cyclophosphamide in Ethiopian breast cancer patients. Front Pharmacol. 2020;11:406.
doi: 10.3389/fphar.2020.00406
pubmed: 32390827
pmcid: 7191301
Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, Fouzia NA, et al. Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:977–83.
doi: 10.1038/bmt.2017.79
pubmed: 28481355
pmcid: 5584518
Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6:1961–8.
doi: 10.1182/bloodadvances.2021006418
pubmed: 34788386
pmcid: 9006295
Liu Q, Liu Z, Wan R, Huang W. Clinical strategies for enhancing the efficacy of CAR T-cell therapy for hematological malignancies. Cancers. 2022;14:4452.
doi: 10.3390/cancers14184452
pubmed: 36139611
pmcid: 9496667
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.
doi: 10.1126/scitranslmed.3008226
pubmed: 24553386
pmcid: 4684949
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52.
doi: 10.1016/S0140-6736(20)31366-0
pubmed: 32888407